Influenza Vaccines Market, By Vaccine Type (Quadrivalent and Trivalent), By Route of administration (Nasal Spray and Injection), By Age-Group ( Pediatric and Adult), Technology (Egg-Based and Cell-Culture) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2034

Influenza Vaccines Market was valued at US$ 7.5 Billion in 2024 and is projected to grow at a CAGR of 8.20% to reach US$ 15.5 Billion by 2034.

[PDF]The Influenza Vaccines Market focuses on providing vaccines for the protection against the four influenza viruses – Influenza A (H1N1) virus, influenza A (H3N2) virus and two other influenza B viruses.

The continuous increasing awareness by the government authorities for influenza vaccine is anticipated to bring an increase in the growth of the target market. The government has been supporting and providing monitoring facilities related to influenza vaccination on the national and international levels to track the supply, distribution, and administration of vaccines. Additionally, a rise in government funding and an increase in major market participants' investments have aided in the development of therapeutically effective vaccinations, which is what is driving the growth of the Influenza Vaccine Market.

After the Covid19 pandemic, the government and different healthcare professionals have pushed for free vaccinations for residents, and as a result, flu vaccination rates have reached their highest during the epidemic, which in turn have boosted the growth of the Influenza Vaccines Market

Increasing clinical trials for development of new products

The rise in the number of clinical trials for the development of new products by numerous market players is a key factor leading to the growth of the target market.

For instance, on May 2022, Osivax, a biopharmaceutical company declared an update on its clinical development plan of its lead candidate – OVX836. It is Osivax’ T-cell based influenza candidate which was developed using the company’s private oligoDOM nanoparticle technology platform. It was designed to induce immune responses against a nucleoprotein which was a highly conserved internal antigen across flu strains. Such steps taken by these developing industries eventually help in boosting the growth of the Influenza Vaccines Market.

Increasing awareness schemes by the government authorities

It is projected that the target market will develop more rapidly as a result of the government authorities' ongoing increase in knowledge of the flu vaccination. In order to track the supply, distribution, and administration of vaccinations, the government has been supporting and providing monitoring facilities for influenza vaccination on a national and worldwide level. The development of therapeutically effective vaccines has also benefited from increased government funding and investments from key industry players, which is what is propelling the growth of the Influenza vaccine market.

For instance, in October 2021, the U.K. government launched a campaign which was supported by charities and various healthcare organizations to encourage the eligible ones to get the necessary protection with a free flu vaccine. The campaign had launched the flu programme for a time period of one year (2021 – 2022).

Restrains:

The high cost for the vaccine development across the globe is the major factor which has hindered the growth of the Influenza Vaccines Market.

For instance, on June 22, 2021, a scientific publication called BMJ published an article concerning expensive vaccines.  The Centers for Disease Control and Prevention (CDC) paid a greater price than in previous seasons for seven million doses of vaccine when bought in bulk through the agreements for the 2020–21 flu season.

 

Influenza Vaccines Market is segmented the basis of Vaccine Type, Route of Administration, Age-Group, Technology, and Region.

Vaccine Type Insights

On the basis of Vaccine Type, the Influenza Vaccines Market is segmented into Quadrivalent and Trivalent). The quadrivalent vaccine type segment is expected to dominate the market growth as it accounted for the majority of revenue in 2020 owing to its ability to immunize all the four strains of the virus (two A subtypes and two B subtypes).

Route of Administration Insights

On the basis of route of administration, the Influenza Vaccines Market is segmented into Nasal Spray and Injection. The Injection Route of Administration Segment is expected to dominate the growth of the Influenza Vaccines Market as the preferred route of administration for influenza vaccines is by intramuscular injection.

Age Group Insights

On the basis of Age Group, the Influenza Vaccines Market is segmented into Pediatric and Adult. The adult age group segment is expected to dominate the market growth during the forecast period, owing to the higher chances of developing serious complications from influenza due to their weaker immune response.

Technology Insights

On the basis of Technology, the Influenza Vaccines Market is segmented into Egg Based and Cell- Culture. The egg-based technology segment is expected to dominate the market growth as it is mostly used in the production of both inactivated as well as live-attenuated vaccines. 

Regional Insights:

On the basis of region, the Influenza Vaccines Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America region segment is expected to dominate the market growth in the forecast period, as it had accounted for the largest influenza vaccine market share in 2020. This rising prevalence of influenza in the region, the increase in government focus on various immunization programs, the growing development of new vaccines, as well as the growth in technological advancements for vaccine administrations is anticipated to bring an upsurge in the Influenza Vaccines Market.

Report Scope:

Attribute	Details
Base year for estimation	2024
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Vaccine Type - Quadrivalent and Trivalent. By Route Of Administration - Nasal Spray and Injection. By Age Group - Pediatric and Adult. By Technology - Egg Based and Cell-Culture.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Influenza Vaccines Market report based on Vaccine Type, Route of Administration, Age Group, Technology and Region:

Influenza Vaccines Market, By Type:

• Quadrivalent
•  Trivalent.

Influenza Vaccines Market, By route of administration:

• Nasal Spray
• Injection.

Influenza Vaccines Market, By Age Group:

• Pediatric
• Adults

Influenza Vaccines Market, By Technology:

• Egg Based
• Cell- Culture

Influenza Vaccines Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

 

Recent Development:

• In August 2022, A UK startup called Emergex intended to produce enough of its all-purpose influenza vaccine for use in Phase I human trials. Emergex claims that their vaccine differs from conventional influenza vaccinations in that it primes CD8+ T cells specific to influenza that can recognize the same peptides when they are presented on the surface of infected cells.

• In 2022, Abbott launched a vaccine named – “Influvac Tetra 2022/2023”. It works by exposing the host to a small dose of the flu virus which in turn helps induce immunity in the body.
• In July 2022, The FDA (Food and Drug Administration) approved Sanofi’s lincensure request for a vaccine approval for the 2022-2023 flu season, which included Fluzone High Dose Quadrivalent (influenza Vaccine), Flublok Quadrivalent (influenza vaccine) and Fluzone Quadrivalent (influenza vaccine).

The key players operating the Influenza Vaccines Market includes, AstraZeneca Plc, GlaxoSmithKline, Sanofi, FOLIA BIOTECH, Genentech, Green Cross Moderna Therapeutics, Shijiazhuang Yiling Pharmaceutical, SK Chemicals, and UNM Pharma.

• AstraZeneca Plc *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• GlaxoSmithKline
• Sanofi
• FOLIA BIOTECH
• Genentech
• Green Cross Moderna Therapeutics
• Shijiazhuang Yiling Pharmaceutical
• SK Chemicals
• UNM Pharma.

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Influenza Vaccines Strategies
     • Key Questions this Study will Answer

     • By Type (Air-Insulated Switchgears, And Gas-Insulated Switchgears)

       By Application (Power Generation, Oil & Gas, Utilities Sector, And Industrial)

       By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) 

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Influenza Vaccines Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• •  AstraZeneca Plc

  • GlaxoSmithKline

  • Sanofi

  • FOLIA BIOTECH

  • Genentech

  • Green Cross Moderna Therapeutics

  • Shijiazhuang Yiling Pharmaceutical

  • SK Chemicals

  • UNM Pharma.

1. The Last Word
   • Future Impact
   • About Us
   • Contact